3 Dividend Stocks to Buy Hand Over Fist in June

Source Motley_fool

Key Points

  • Pfizer has a rich pipeline of drugs in development, at least some of which are likely to sell well.

  • UPS has turned away from Amazon.com and toward more profitable deliveries.

  • The Schwab U.S. Dividend Equity ETF offers both dividend income and growth.

  • 10 stocks we like better than Pfizer ›

If you want to be a savvy investor, you should know what this table is telling you:

Dividend-Paying Status

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

Average Annual Total Return, 1973-2025

Dividend growers and initiators

10.22%

Dividend payers

9.20%

No change in dividend policy

6.87%

Dividend non-payers

4.21%

Dividend shrinkers and eliminators

(0.96%)

Equal-weighted S&P 500 index

7.74%

Data source: Ned Davis Research and Hartford Funds.

As it starkly shows, it's hard to beat healthy and growing dividend-paying stocks if you're looking to boost your wealth over time. Here, then, are three to consider.

Someone is smiling behind some fanned out bills.

Image source: Getty Images.

1. Pfizer

Let's start with pharmaceutical giant Pfizer (NYSE: PFE). It's a compelling dividend payer largely because of its dividend yield -- recently a fat 6.7%. That payout is hefty in large part because the stock has averaged annual losses of about 7% over the past three years. (It's up 17% over the past year, though, as of June 4.) When a stock's price falls, its dividend yield rises, so many high-yielders have been facing some kind of struggle.

A key challenge for Pfizer has been the patent protection expiration of some of its biggest sellers. That's an issue for every pharmaceutical company, and one which they typically tackle by having a pipeline filled with promising drugs in development -- and/or by acquiring such promising drugs from other companies. Pfizer is doing both.

Pfizer's shares seem undervalued, too, with a recent forward P/E ratio of 9.0, well below the five-year average of 9.7.

2. United Parcel Service (UPS)

United Parcel Service (NYSE: UPS) is another stock with a massive dividend yield, recently 7.7%. It, too, has posted average annual losses over the past three years, 8.6%. But as with Pfizer, there's a lot to like about UPS.

Detractors are wringing their hands over UPS's decision to cut back on the deliveries it makes for Amazon.com (NASDAQ: AMZN), but that's far from a death knell. Others see that as a smart move, because that arrangement has largely been a low-profit-margin one for UPS. The company is now focusing more on serving higher-margin customers, such as small and medium-sized businesses and the healthcare sector.

UPS' first-quarter report featured overall domestic revenue down 2.3%, while revenue per package grew 6.5%. Internationally, revenue rose by 3.8%, with revenue per package popping by 12.1%. The company's shares seem reasonably valued, with a recent forward P/E ratio of 14, a bit below the five-year average of 15. Long-term believers in the UPS plan will be paid handsomely while they wait.

3. Schwab U.S. Dividend Equity ETF

My last suggestion is not exactly a stock. It's an exchange-traded fund (ETF) that trades like a stock. It's the Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD), which recently yielded a solid 3.25% and parks investors' money across roughly 100 dividend payers such as Qualcomm (NASDAQ: QCOM), Texas Instruments (NASDAQ: TXN), and UnitedHealth Group (NYSE: UNH). (UPS shares were among its top 30 holdings recently, too.)

The ETF offers a compelling mix of both income and growth -- indeed, it was up nearly 20% year to date as of June 4. It's a good choice instead of investing in individual dividend payers on your own or in addition to doing so.

Should you buy stock in Pfizer right now?

Before you buy stock in Pfizer, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $443,191!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,258,838!*

Now, it’s worth noting Stock Advisor’s total average return is 941% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of June 7, 2026.

Selena Maranjian has positions in Amazon, Pfizer, and Schwab U.S. Dividend Equity ETF. The Motley Fool has positions in and recommends Amazon, Pfizer, Qualcomm, Texas Instruments, and United Parcel Service. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Cardano Tumbles 10% in Deepening Crypto Rout to Post Worst Day Since FebruaryCardano shed 10% on Thursday to hit $0.1925, marking its worst daily performance since Feb. 5 as a broader digital asset selloff dragged down Bitcoin and Ethereum.
Author  Mitrade Team
6 Month 04 Day Thu
Cardano shed 10% on Thursday to hit $0.1925, marking its worst daily performance since Feb. 5 as a broader digital asset selloff dragged down Bitcoin and Ethereum.
placeholder
Asian Currencies Steady Near Lows as Yen Hovering Near 160 Triggers Intervention WatchAsian markets stabilized following a sharp selloff, balanced by a fragile Middle East ceasefire and strong U.S. economic data that fueled expectations of prolonged high Federal Reserve interest rates.
Author  Mitrade Team
6 Month 04 Day Thu
Asian markets stabilized following a sharp selloff, balanced by a fragile Middle East ceasefire and strong U.S. economic data that fueled expectations of prolonged high Federal Reserve interest rates.
placeholder
Oil Rallies Near $96 as Hezbollah Rejects Ceasefire, Choking Hormuz FlowsOil prices advanced on Friday, pushing Brent toward $96, after Hezbollah rejected a U.S.-brokered ceasefire. The diplomatic breakdown stalls broader U.S.-Iran peace talks and keeps vital Strait of Hormuz oil flows restricted.
Author  Mitrade Team
6 Month 05 Day Fri
Oil prices advanced on Friday, pushing Brent toward $96, after Hezbollah rejected a U.S.-brokered ceasefire. The diplomatic breakdown stalls broader U.S.-Iran peace talks and keeps vital Strait of Hormuz oil flows restricted.
placeholder
Tech Rout and Rate Hike Fears Drag Asian Stocks LowerAsian equities retreated on Friday as investors locked in technology profits ahead of U.S. payroll data, while South Korean labor friction and Japanese rate-hike speculation compounded regional market losses.
Author  Mitrade Team
6 Month 05 Day Fri
Asian equities retreated on Friday as investors locked in technology profits ahead of U.S. payroll data, while South Korean labor friction and Japanese rate-hike speculation compounded regional market losses.
placeholder
Gold Slumps as Dwindling Iran Peace Hopes Reignite Fed Rate ApprehensionGold headed for its worst week since May as collapsed Middle East peace talks stoked inflation fears, driving dollar inflows ahead of crucial U.S. nonfarm payrolls data.
Author  Mitrade Team
6 Month 05 Day Fri
Gold headed for its worst week since May as collapsed Middle East peace talks stoked inflation fears, driving dollar inflows ahead of crucial U.S. nonfarm payrolls data.
goTop
quote